in Addition to reducing cases of the disease, vaccination greatly reduces the surgical mortalityà associated with the flu.
thereà, which gives the vaccine lasts for 6-12 months, therefore, it is necessary to repeat each year the vaccination.
The vaccination reaches the maximum efficacy after approximately 4 weeks from the inoculation. The viruses that cause influenza change almost every year, therefore, there is no vaccine final.
The World Organisation of the Sanità fixed every year, the composition of the vaccine.
the Composition of the influenza vaccine for the 2004-2005 season Circular.1 July 2004 the Ministry of Health.
In the season of epidemic of 2003-2004 in many of the Countries have circulating virus(H3N1), A(H1N1), A(H1N2) and B.
The subtypes A(H1N1) and A(H1N2) were isolated from sporadic cases in most of the weights, while only two Countries reported outbreaks.
The tests showed that these subtypes had similar characteristics to the strain A/New Caledonia/20/99.
viruses of subtype A(H3N2) were predominant and associated with epidemics extended in many Countries; they showed, in most cases, the similarity with the strain A/Fujian/411/2002.
type B viruses have caused sporadic cases, but not causing epidemics; most of it has been found antigenicamante similar to the strain B/Shanghai/361/2002.
On the basis of the findings of epidemiological and serological evidence regarding the circulation of influenza viruses in the past season, obtained thanks to the network of surveillance and control of influenza, which extends into 82 countries of the world, including Italy, the World Organization of the Sanità recommends that the vaccine be used for the next campaign 2004-2005 in the northern hemisphere, is a trivalent vaccine containing the following antigens: antigen similar to the strain A/New Caledonia/20/99 (H1N1) antigen similar to the strain A/Fujian/411/2002 (*1) (H3N2) antigen similar to the strain B/Shanghai/361/2002 (*2) (*1) the strain used for vaccine production is the A/Wyoming/3/2003; is equally available to the strain A/Kumamoto/102/2002. (*2) strains and the B/Shanghai/361/2002 and B/Jiangsu/10/2003 are one of the virus vaccine potential.
The quantityà antigenic standardized for each vaccine strain should, as established by the ad hoc Group on Biotech the Pharmacology of the Commission of the European Union, containing a quantity; of haemagglutinin 15 micrograms per strain and per dose of influenza, with a limit trustee for the 95% not less than 12 micrograms.
dott. Cesare Augusto De Silvestri.